drugset / Trial / NCT00645307

A 52 Week Open Label Extension Trial Following the Recurrence Prevention Study R076477-SCH-301 to Evaluate the Safety and Tolerability of Paliperidone ER in Subjects With Schizophrenia.

NCT00645307

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of the study was an Open Label Extension to the recurrence prevention study to evaluate long-term safety and tolerability of paliperidone ER in subjects with schizophrenia.

Timeline

Start
2004-05
Primary completion
Completion
2006-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Paliperidone Unknown 3 mg
Subject Paliperidone Unknown 15 mg

Indications